COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

Search Clinical Trials

Clinical Trials Category

Reset

All of Us Research Program

Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.

6 results for "Cancer" and "Head and Neck Cancers" and "Leukemia"

A Phase 1, Multicenter, Open-label, Multiple-ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of KPG-818 in Subjects with Hematological Malignancies

Open-label, multiple-ascending dose study to evaluate the safety, PK, and preliminary clinical activity of KPG-818 as a single agent in adult subjects with selected hematological malignancies, except for multiple myeloma indication. KPG-818 will be used in combination with dexamethasone for dose escalation and dose expansion. The study will consist of 2 parts: Part 1 dose escalation and Part 2 dose expansion.
Protocol No
KANGPU-KPG-818-HEM-101
Sub Category
Hematologic/Blood Related Cancers, Early Phase/Multiple Disease Site Cancers

A Phase 1b Trial of Magrolimab Monotherapy or Magrolimab in Combination with Azacitidine in Patients with Hematological Malignancies

The purpose of this study is to test the safety of Hu5F9-G4 alone, or in combination with azacitidine in patients with blood cancers such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Other purposes of this study are to determine the best dose of Hu5F9-G4, the quantity of Hu5F9-G4 in your blood, the side effects it has on your body, and whether or not it can improve your cancer.
Protocol No
FORTYSEVEN-5F9005
Sub Category
Early Phase/Multiple Disease Site Cancers

A Phase 1, First-in-Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody-Based Molecule, in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Intermediate-2/High Risk Myelodysplastic Syndrome

The purpose of the study is to find the answers to these research questions:
What are the side effects of MGD006?
What is the highest dose of MGD006 that can be given safely?
How long does MGD006 stay in the blood?
How long does it take for MGD006 to leave the body?
Is MGD006 a possible treatment for AML?
Protocol No
MACROGENICS-CP-MGD006-01
Sub Category
Hematologic/Blood Related Cancers, Early Phase/Multiple Disease Site Cancers

A Multi-Center, Open Label Phase 1/2 Study of Cyt-0851, an Oral Rad51 Inhibitor, in Patients with Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors

A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in Patients With Relapsed/Refractory B-Cell Malignancies And Advanced Solid Tumors
Protocol No
CYTEIR-CYT-0851-01-REFMAL639
Sub Category
Hematologic/Blood Related Cancers, Early Phase/Multiple Disease Site Cancers, Sarcoma, Head and Neck Cancers, Gynecologic Cancers, Gastrointestinal Cancers, Breast Cancers